611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Cancer
Resources
Basic InformationLatest News
Drug Offers Hope Against a Tough-to-Treat Blood CancerMore Antibiotics, Higher Odds for Colon Cancer?U.S. Task Force Updates Breast Cancer Gene Testing RecommendationsNew Treatments Could Be Powerful Weapons Against Brain TumorsAmerica's Obesity Epidemic May Mean Some Cancers Are Striking SoonerAre You Still Putting Off Colon Cancer Screening?New Study Finds a Family Risk for Blood CancerNew DNA Blood Test May Help Guide Breast Cancer TreatmentDespite Cancer Screening, 'Oldest Old' Have Low Survival Odds: StudyRoutine Screening for Pancreatic Cancer Not Warranted, Expert Panel SaysAHA News: Common Prostate Cancer Treatment May Increase Risk of Fatal Heart ConditionFinances Affect Women's Choice of Breast Cancer Treatment: StudyDrug Duo May Be an Advance Against a Common LeukemiaVitamin A Linked to Lower Odds of Common Skin CancerChildhood Cancer Steals Over 11 Million Years of Healthy Life: StudySome of Most Common, Deadly Cancers Get the Least Research MoneyBreast Implants Tied to Rare Cancer RecalledNew Test Can Pinpoint Which Pancreatic Cysts Might Turn CancerousCan a Broken Heart Contribute to Cancer?Hurricanes Can Hurt Survival Odds Among Those With CancerNewer Lung Cancer Screening Saves More LivesSugary Sodas, Juices Tied to Higher Cancer RiskHormone Treatment for Prostate Cancer Linked to Heightened Alzheimer's RiskMillions of Life Years, Billions of Dollars Lost to Cancer Each YearMS Linked to Higher Cancer RiskCancer Risk Rises After Iodine Rx for Overactive Thyroid: StudyEarly Risers May Be a Little Less Likely to Get Breast CancerHPV Vaccine Making Headway Against Cancer-Causing Virus WorldwideNew Urine Test Might Show Whether Prostate Cancer Needs Treatment9/11 Dust Linked to Prostate Cancer in First RespondersBetter Treatments Needed to Boost Brain Cancer Survival: StudyCancer Survivors May Have Lower Odds for DementiaHeart Disease Is Lasting Threat to Breast Cancer SurvivorsHow Do Birth Defects Affect Childhood Cancer Risk?More Than 5 Million U.S. Cancer Survivors Deal With Chronic PainStatins May Lower Risk of Stroke After Cancer RadiotherapyYogurt Might Help Men Avoid Colon Cancer: StudyMany Advanced Colon Cancers Were 'Born' Ready to Spread'Double-Edged Sword': Lung Cancer Radiation Rx May Raise Heart Attack RiskYour Drinking Water May Harbor Cancer-Causing Nitrate: StudyNo Needle Prick: Laser-Based Test Hunts Stray Melanoma Cells in BloodChemoimmunotherapy Regimen Approved to Treat DLBCLCancer Survivors Predicted to Top 22 Million by 2030Guard Your Skin Against the Summer Sun'Focused' Radiation Could Lighten Treatment Burden for Early Breast Cancer1 in 4 Cancer Survivors Faces 'Financial Hardship' Due to Medical CostsFew Prostate Cancer Patients Are Getting Checkups They NeedTesticular Cancer Treatment Unlikely to Trigger Birth DefectsIs MRI Screening Worth It for Breast Cancer Survivors?Obamacare May Have Helped Close 'Race Gap' in Cancer Care
LinksBook ReviewsSelf-Help Groups
Related Topics

Medical Disorders
Pain Management

Chemoimmunotherapy Regimen Approved to Treat DLBCL


HealthDay News
Updated: Jun 11th 2019

new article illustration

TUESDAY, June 11, 2019 (HealthDay News) -- Polivy (polatuzumab vedotin-piiq), a novel antibody-drug conjugate, received approval to treat patients with diffuse large B-cell lymphoma (DLBCL) in combination with bendamustine and rituximab, the U.S. Food and Drug Administration announced today. The combination was approved for patients whose disease has progressed or returned after at least two previous therapies.

Approval was based on a study of 80 patients with relapsed or refractory DLBCL randomly assigned to receive either Polivy with bendamustine and rituximab or bendamustine and rituximab alone. Researchers found a complete response rate of 40 percent with Polivy plus bendamustine and rituximab compared with 18 percent with bendamustine and rituximab alone. Twenty-five patients achieved a partial or complete response with Polivy plus bendamustine and rituximab; 64 percent of these patients had a duration of response of six months or longer and 48 percent achieved a duration of response of at least one year.

The most commonly reported side effects of the combination of Polivy plus bendamustine and rituximab included neutropenia, thrombocytopenia, anemia, peripheral neuropathy, fatigue, diarrhea, fever, decreased appetite, and pneumonia.

Patients should be closely monitored for infusion-related reactions, low blood counts, fatal or serious infections, tumor lysis syndrome, hepatotoxicity, and progressive multifocal leukoencephalopathy. The FDA noted that women of reproductive age should be advised to use effective contraception during treatment and for three months following the last dose, and those who are pregnant or breastfeeding should not be treated with Polivy.

Approval of Polivy was granted to Genentech.

More Information